Detalles de la búsqueda
1.
Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.
Neurourol Urodyn
; 39(8): 2206-2222, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32827230
2.
A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.
J Clin Rheumatol
; 21(8): 411-8, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26580304
3.
Comparison of Healthcare Costs for Women with Treated Versus Untreated Vasomotor Symptoms Due to Menopause.
Adv Ther
; 41(5): 1885-1895, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38467985
4.
Novel presynaptic assay system revealed that metformin ameliorates exaggerated synaptic release and Munc18-1 accumulation in presynapses of neurons from Fragile X syndrome mouse model.
Neurosci Lett
; 810: 137317, 2023 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37286070
5.
Association between vasomotor symptom frequency and weight gain in the Study of Women's Health Across the Nation.
Menopause
; 30(7): 709-716, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37314873
6.
Treatment and resource utilization for menopausal symptoms in the United States: a retrospective review of real-world evidence from US electronic health records.
Menopause
; 30(1): 70-79, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36576444
7.
Association of menopausal vasomotor symptom severity with sleep and work impairments: a US survey.
Menopause
; 30(9): 887-897, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37625086
8.
Practice patterns and perspectives regarding treatment for symptoms of menopause: qualitative interviews with US health care providers.
Menopause
; 30(2): 128-135, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36696636
9.
Assessment of women's treatment preferences for vasomotor symptoms due to menopause.
Expert Rev Pharmacoecon Outcomes Res
; 23(10): 1117-1128, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37650213
10.
Impact of sleep disturbances on employment and work productivity among midlife women in the US SWAN database: a brief report.
Menopause
; 28(10): 1176-1180, 2021 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34469936
11.
Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries.
J Am Med Dir Assoc
; 22(6): 1300-1306, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33071158
12.
A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA.
Drugs Aging
; 38(12): 1075-1085, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34746992
13.
Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Case-Control Cohort Analysis.
Adv Ther
; 37(11): 4599-4613, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32910419
14.
Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
Adv Ther
; 37(8): 3584-3605, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32638205
15.
Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression.
Clinicoecon Outcomes Res
; 11: 257-270, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30936731
16.
Treatment and comorbidities of multiple sclerosis in an employed population in Japan: analysis of health claims data.
Neurodegener Dis Manag
; 8(2): 97-103, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29694267
17.
Serum uric acid levels and the risk of flares among gout patients in a US managed care setting.
Curr Med Res Opin
; 33(1): 117-124, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27659103
18.
Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review.
J Rheumatol
; 44(3): 388-396, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28148699
19.
The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
Clin Ther
; 38(7): 1710-25, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27269247
20.
Febuxostat in the management of gout: a cost-effectiveness analysis.
J Med Econ
; 19(3): 265-76, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26535593